NCT01930162View on ClinicalTrials.gov

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 7, 2014

Primary Completion Date

August 29, 2016

Study Completion Date

August 29, 2016

Conditions
Single Umbilical Cord Blood TransplantationNon-myeloablative ConditioningAcute Lymphocytic LeukemiaMyelodysplastic SyndromeNon-Hodgkin's LymphomaMultiple MyelomaChronic Lymphocytic Leukemia
Interventions
DRUG

HSC835

HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).

Trial Locations (1)

55455

Novartis Investigative Site, Minneapolis

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY